1. State budget institution of higher professional education «Samara State Medical University» Ministry of Health of the Russian Federation (Samara, Russian Federation)

Keywords:consensus of the Working Group III,diagnosis and treatment of H.pylori-infection,cancer prevention

Abstract:The purpose of the review. Outline the main points of consensus III Working Group Italian for the diagnosis and treatment of H.pylori-infection. The work of the Working Group III was the clarification of certain provisions of the Maastricht IV consensus, and, namely, the nature of H.pylori relationship with gastroesophageal reflux disease, functional dyspepsia, NSAID / aspirin gastropathy, extra-gastric diseases, detailed scope of the invasive and non-invasive methods of investigation, treatment algorithms updated H.pylori-infection antibiotic growth conditions. Indented understanding of the role of H.pylori eradication in the prevention of gastric cancer.

• References total 84 ⇓ :: .
  1. Zagari R. M., Romano M., Ojetti V., et al. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015 // Digestive and Liver Disease. - 2015. - Vol. 47. - Р. 903 - 912.
  2. Malfertheiner P., Megraud F., O’Morain C. A., et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report // Gut. - 2012. - Vol. 61. - Р. 646 - 64.
  3. Gisbert J. P., Calvet X. Helicobacter pylori test and treat strategy for managementof dyspepsia: a comprehensive review // Clinical and Translational Gastroenterology. - 2013. - Vol. 28. - e32.
  4. Eusebi L. H., Zagari R. M., Bazzoli F. Epidemiology of Helicobacter pylori infection // Helicobacter. - 2014. - Vol. 19 (Suppl. 1). - Р. 1 - 5.
  5. Zagari R. M., Law G. R., Fuccio L., et al. Epidemiology of functional dyspepsia andsubgroups in the Italian general population: an endoscopic study //Gastroenterology. - 2010. - Vol. 138. - Р. 1302 - 11.
  6. Mana F., Vandebosch S., Miendje Deyi V., et al. Prevalence of and risk factors for H.pylori infection in healthy children and young adults in Belgium anno 2010/2011 // Acta Gastroenterol Belg. - 2013. - Vol. 76. - Р. 381 - 5.
  7. Rossi S., Crocetti E., Capocaccia R., et al. Estimated of cancer burden in Italy //Tumori. - 2013. - Vol. 99. - Р. 416 - 24.
  8. Zagari R. M., Fuccio L., Bazzoli F. Investigating dyspepsia // BMJ 2008. - 337a: 1400.
  9. Moayyedi P. Helicobacter pylori eradication for functional dyspepsia: whatare we treating?: Comment on «Helicobacter pylori eradication in functionaldyspepsia» // Archives of Internal Medicine. - 2011. - Vol. 171. - Р. 1936 - 7.
  10. Ronkainen J, Agréus L. Epidemiology of reflux symptoms and GORD // Best Practice & Research Clinical Gastroenterology. - 2013. - Vol. 27. - Р. 325 - 37.
  11. Lee Y. C., Chen T. H., Chiu H. M., et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention // Gut. - 2013. - Vol. 62. - Р. 676 - 82.
  12. Yaghoobi M., Farrokyar F., Yuan Y., et al. Is there an increased risk of GERD after Helicobacter pylori eradication? A meta-analysis //American Journal of Gastroenterology. - 2010. - Vol. 105. - Р. 1007 - 13.
  13. Qian B., Shijie M., Shang L., et al. Effect of HP eradication on gastroesophageal reflux disease //Helicobacter. - 2011. - Vol. 16. - Р. 255 - 65.
  14. Fox J. G., Kuipers E. J. Long-term proton pump inhibitor administration, HP and gastric cancer: lessons from the gerbil // Gut. - 2011. - Vol. 60. - Р. 567 - 8.
  15. Abraham N. S., Hlatky M. A., Antman E. M., et al. Expert Consensus Documenton the concomitant use of proton pump inhibitors and thienopyridines: afocused update of the ACCF/ACG/AHA 2008 expert consensus document onreducing the gastrointestinal risks of antiplatelet therapy and NSAID use: areport of the American College of Cardiology Foundation Task Force on ExpertConsensus Documents // Circulation. - 2010. - Vol. 122. - Р. 2619 - 33.
  16. Levi M. M., Eerenberg E., Löwenberg E., et al. Bleeding in patients using new anti-coagulants or antiplatelet agents: risk factors and management //Netherlands Journal of Medicine. - 2010. - Vol. 68. - Р. 68 - 76.
  17. Qu X. H., Huang X. L., Xiong P., et al. Does Helicobacter pylori infection play a role iniron deficiency anemia? A meta-analysis // World Journal of Gastroenterology. - 2010. - Vol. 16. - Р. 886 - 96.
  18. Goddard A. F., James M. W., McIntyre A. S., et al. Guidelines for the management of iron deficiency anaemia // Gut. - 2011. - Vol. 60. - Р. 1309 - 16.
  19. Huang X., Qu X., Yan W., et al. Iron deficiency anaemia can be improved after eradication of Helicobacter pylori // Postgraduate Medical Journal. - 2010. - Vol. 86. - Р. 272 - 8.
  20. Yuan W., Li Yumin, Yang Kehu, et al. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials //Scandinavian Journal of Gastroenterology. - 2010. - Vol. 45. - Р. 665 - 76.
  21. Annibale B., Capurso G., Lahner E., et al. Concomitant alterations in intra-gastric pH and ascorbic acid concentration in patients with Helicobacter pylori gastritis and associated iron deficiency anaemia // Gut. - 2003. - Vol. 52. - Р. 496 - 501.
  22. Franchini M., Cruciani M., Mengoli C., et al. Effect of Helicobacter pylorieradication on platelet count in idiopathic thrombocytopenic purpura: a sys-tematic review and meta-analysis //Journal of Antimicrobial Chemotherapy. -2007. - Vol. 60. - Р. 237 - 46.
  23. Stasi R., Sarpatwari A., Segal J. B., et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review // Blood. - 2009. - Vol. 113. - Р. 1231 - 40.
  24. Arnold D. M., Bernotas A., Nazi I., et al. Platelet count response to HP treatment in patients with immune thrombocytopenic purpura with and without HP infection: a systematic review //Haematologica. - 2009. - Vol. 94. - Р. 850 - 6.
  25. Lahner E., Persechino S., Annibale B., et al. (Other than iron) and Helicobacter pylori infection: a systematic review // Helicobacter. - 2012. - Vol. 17. - Р. 1 - 15.
  26. Wang Z. W., Yan L., Huang L. Y., et al. Helicobacter pylori infection contributesto high risk of ischemic stroke: evidence from a meta-analysis // Journal of Neurology. - 2012. - Vol. 259. - Р. 2527 - 33.
  27. Gravina A. G., Federico A., Ruocco E., et al. Helicobacter pylori infection but notsmall intestinal bacterial overgrowth may play a pathogenic role in rosacea //United European Gastroenterology Journal. - 2015. - Vol. 3. - Р. 17 - 24.
  28. Ferwana M, Abdulmajeed I, Alhajiahmed A, et al. Accuracy of urea breath testin Helicobacter pylori infection: meta-analysis // World Journal of Gastroenterology. - 2015. - Vol. 2. - Vol. 1305 - 14.
  29. Gisbert J. P., De La M. F., Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of infection: a systematic review and meta-analysis //American Journal of Gastroenterology. - 2006. - Vol. 101. - Р. 1921 - 30.
  30. Calvet X., Lario S., Ramirez-Lazaro M. J., et al. Accuracy of monoclonal stool tests for determining cure of Helicobacter pylori infection after treatment //Helicobacter. - 2010. - Vol. 15 (3). - Р. 201 - 05.
  31. Vaira D., Gatta L., Ricci C., et al. Helicobacter pylori: diseases, tests and treatment //Digestive and Liver Disease. - 2001. - Vol. 33. - Р. 788 - 94.
  32. Sanchez-Delgado J., Genè E., Suarez D., et al. Has HP prevalence in bleeding peptic ulcer been underestimated? A meta-regression //American Journal of Gastroenterology. - 2011. - Vol. 106. - Р. 398 - 405.
  33. Ekstrom A. M., Held M., Hansonn L. E., et al. Helicobacter pylori in gastriccancer established by CagA immunoblot as a marker of past infection //Gastroenterology. - 2001. - Vol. 121. - Р. 784 - 91.
  34. De Francesco V., Zullo A., Ierardi E., et al. Phenotypic and genotypic Helicobacterpylori clarithromycin resistance and therapeutic outcome: benefits and limits //Journal of Antimicrobial Chemotherapy. - 2010. - Vol. 65. - Р. 327 - 32.
  35. Rimbara E., Noguchi N., Kawai T., et al. Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the levelof resistance and identification of a resistance conferring mutation in GyrB //Helicobacter. - 2012. - Vol. 17. - Р. 36 - 42.
  36. Cambau E., Allerheiligen V., Coulon C., et al. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacterpylori // Journal of Clinical Microbiology. - 2009. - Vol. 47. - Р. 3600 - 7.
  37. De Francesco V., Zullo A., Giorgio F., et al. Change of point mutations in the H.pylori rRNA associated with clarithromycin resistance in Italy // Journal of Medical Microbiology. - 2014. - Vol. 63. - Р. 453 - 7.
  38. Liu Q., Qi D., Kang J., et al. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection //European Journal of Gastroenterology and Hepatology. - 2015. - Vol. 27. - Р. 221 - 5.
  39. Figura N., Crabtree J. E., Dattilo M. In-vitro activity of lansoprazole against Helicobacter pylori //Journal of Antimicrobial Chemotherapy. - 1997. - Vol. 39. - Р. 585 - 90.
  40. Villoria A., Garcia P., Calvet X., et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication //Alimentary Pharmacology and Therapeutics. - 2008. - Vol. 28. - Р. 868 - 77.
  41. Farup P. G., Lange O. J., Tholfsen J., et al. The effect of Helicobacter pylori retreatment with ranitidine bismuth citrate, clarithromycin, and metronidazole depends on the first-line therapy //Journal of Clinical Gastroenterology 2002. - Vol. 35. - Р. 379 - 82.
  42. Almeida N., Romãozinho J. M., Donato M. M., et al. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study //Helicobacter 2014. - Vol. 19. - Р. 90 - 7.
  43. Megraud F., Coenen S., Versporten A., et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption // Gut. - 2013. - Vol. 62. - Vol. 34 - 42.
  44. Yang Y., Ford A. C., Khan K. J., et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database of Systematic Reviews 2013. Art No: CD370083.
  45. Zullo A., Esposito G., Ridola L., et al. Prevalence of lesions detected atupper endoscopy: an Italian survey //European Journal of Internal Medicine. - 2014. - Vol. 25. - Р. 772 - 6.
  46. Zullo A., Esposito G., Ridola L., et al. Prevalence of lesions detected atupper endoscopy: an Italian survey //European Journal of Internal Medicine. - 2014. - Vol. 25. - Р. 772 - 6.
  47. Gatta L., Vakil N., Vaira D., et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy // BMJ. - 2013. - Vol. 347. - f4587.
  48. Molina-Infante J., Romano M., Fernandez-Bermejo M., et al. Optimized non-bismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance // Gastroenterology. - 2013. - Vol. 145. - Р. 121 - 8.
  49. Malfertheiner P., Bazzoli F., Delchier J., et al. Helicobacter pylori eradication witha capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: arandomised, open-label, non-inferiority, phase 3 trial, Pylera Study Group //Lancet. - 2011. - Vol. 377. - Р. 905 - 13.
  50. Liou J. M., Lin J., Chang C. Y., et al. Levofloxacin-based and clarithromycin-basedtriple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with cross-over design // Gut. - 2010. - Vol. 59. - Р. 572 - 8.
  51. Federico A., Gravina A. G., Miranda A., et al. Eradication of Helicobacter pylori infection: which regimen first? //World Journal of Gastroenterology. - 2014. - Vol. 20. - 665 - 72.
  52. Federico A., Nardone G., Gravina A. G., et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection //Gastroenterology. - 2012. - Vol. 143. - Р. 55 - 61.
  53. Saracino I. M., Zullo A., Holton J., et al. High prevalence of primary antibioticresistance in Helicobacter pylori isolates in Italy // Journal of Gastrointestinal and Liver Diseases. - 2012. - Vol. 21. - Р. 363 - 5.
  54. Chung J. W., Lee J. H., Yung H. Y., et al. Second-line Helicobacter pylori eradication: arandomized comparison of 1 week or 2 week bismuth-containing quadruple therapy // Helicobacter. - 2011. - Vol. 16. - Р. 289 - 94.
  55. Rokkas T., Sechophulos P., Robotis I., et al. Cumulative HP eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen // American Journal of Gastroenterology. - 2009. - Vol. 104. - Р. 21 - 5.
  56. Gisbert J. P., Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection //Alimentary Pharmacology and Therapeutics. - 2012. - Vol. 35. - Р. 209 - 21.
  57. Fiorini G., Vakil N., Zullo A., et al. Culture-based selection therapy for patientswho did not respond to previous treatment for Helicobacter pylori infection // Clinical Gastroenterology and Hepatology. - 2013. - Vol. 11. - Р. 507 - 10.
  58. Ruggero P. Use of probiotics in the fight against Helicobacter pylori //World Journal of Gastroenterology. - 2014. - Vol. 5. - Р. 384 - 91.
  59. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccha-romyces boulardii supplementation on Helicobacter pylori eradication ratesandside effects during treatment // Alimentary Pharmacology and Therapeutics. - 2010. - Vol. 32. - Р. 1069 - 79.
  60. Wang Z. H., Gao Q. Y., Fang J. Y. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic com-pound preparation in Helicobacter pylori eradication therapy // Journal of Clinical Gastroenterology. - 2013. - Vol. 47. - Р. 25 - 32.
  61. Zheng X., Lyu L., Mei Z. Lactobacillus-containing probiotic supplemen-tation increases Helicobacter pylori eradication rate: evidence from a meta-analysis // Revista Espanola de Enfermedades Digestivas. - 2013. - Vol. 105. - Р. 445 - 53.
  62. Zojaji H., Ghobakhlou M., Rajabalinia H., et al. The efficacy and safety of adding the probiotic Saccharomyces boulardii to standard triple therapy for eradication of HP: a randomized controlled trial // Gastroenterology and Hepatology from Bed to Bench. - 2013. - Vol. 6 (Suppl. 1). - S99-104.
  63. Manfredi M, Bizzarri B, Sacchero RI, et al. Helicobacter pylori infection inclinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy //Helicobacter. - 2012. - Vol. 17. - Р. 254 - 63.
  64. Ford A. C., Forman D., Hunt R. H., et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials //BMJ. - 2014. - Vol. 348. - g. 3174.
  65. Wang H. L., Zhou P. Y., Liu P., et al. Role of p16 gene promotor methylation in gastric carcinogenesis: a meta-analysis // Molecular Biology Reports. - 2014. - Vol. 41. - Р. 4481 - 92.
  66. Marcos-Pinto R., Dinis-Ribeiro M., Carneiro F., et al. First-degree relatives of early-onset gastric cancer patients show a high risk for gastric cancer: phenotype and genotype profile //Virchows Archiv. - 2013. - Vol. 463. - Р. 391 - 9.
  67. McLean M. H., El-Omar E. M. Genetics of gastric cancer //Nature Reviews Gastroenterology & Hepatology. - 2014. - Vol. 11. - Р. 664 - 74.
  68. Yan S., Li B., Bai Z. Z., et al. Clinical epidemiology of gastric cancer in Hehuang valley of China: a 10-year epidemiological study of gastric cancer //World Journal of Gastroenterology. - 2014. - Vol. 20 (30). - Р. 10486 - 94.
  69. Dorji D., Dendup T., Malaty H. M., et al. JM. Epidemiology of Helicobacter pylori in Bhutan: the role of environment and geographic location // Helicobacter. - 2014. - Vol. 19. - Р. 69 - 73.
  70. Tsukanov V. V., Butorin N. N., Maady A. S., et al. Helicobacter pylori infection, intestinal metaplasia, and gastric cancer risk in Eastern Siberia // Helicobacter. - 2011. - Vol. 16. - Р. 107 - 12.
  71. Rugge M., Correa P., Dixon M. F., et al. Gastric mucosa atrophy: inter-observer consistency using new criteria for classification and grading. Alimentary //Pharmacology and Therapeutics. - 2002. - Vol. 16. - Р. 1249 - 59.
  72. Dinis-Ribeiro M., Areia M., de Vries A. C., et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG). European Society of Pathology, and the Sociedade Portoguesa de Endoscopia Digestiva (SPED) // Endoscopy. - 2012. - Vol. 44. - Р. 74 - 94.
  73. Sanduleanu S., Jonkers D., de Bruine A., et al. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa // Alimentary Pharmacology and Therapeutics. - 2001. - Vol. 15. - Р. 379 - 88.
  74. Fuccio L., Zagari R. M., Eusebi L. H., et al. Meta-analysis: can Helicobacter pylorieradication treatment reduce the risk for gastric cancer? //Annals of Internal Medicine. - 2009. - Vol. 151. - Р. 121 - 8.
  75. Yamaji Y., Watabe H., Yoshida H., et al. High-risk population for gastric cancer development based on serum pepsinogen status and lifestyle factors //Helicobacter. - 2009. - Vol. 14. - Р. 81 - 96.
  76. Ford A. C., Forman D., Hunt R. H., et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials //BMJ. - 2014. - Vol. 348. - g. 3174.
  77. Dinis-Ribeiro M., Yamaki G., Miki K., et al. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening // Journal of Medical Screening. - 2004. - Vol. 11. - Р. 141 - 7.
  78. Rabitti S., Greenwood D., Eusebi L. H., et al. Sensitivity and specificity of thepanel test «Gastropanel» for the non invasive diagnosis of atrophic gastritis //Digestive and Liver Disease. - 2014. - Vol. 46 (Suppl. 2). - S90.
  79. Sinning C., Schaefer N., Standop J., et al. Gastric stump carcinoma - epidemiology and current concepts in pathogenesis and treatment // European Journal of Surgical Oncology. - 2007. - Vol. 33. - Р. 2022 - 6.
  80. Rokkas T., Sechopoulos P., Pistiolas P., et al. Helicobacter pylori infection and gastric histology in first degree relatives of gastric cancer patients: a meta-analysis //European Journal of Gastroenterology and Hepatology. - 2010. - Vol. 22. - Р. 1128 - 31.
  81. Poulsen A. H., Christensen S., McLaughlin J. K., et al. Proton pump inhibitors and risk of gastric cancer: a population based cohort-study // British Journal of Cancer. - 2009. - Vol. 100. - Р. 1503 - 7.
  82. Santibanez M., Alguacil I., Garcia De La Hera M., et al. Occupational exposures and risk of stomach cancer by histological type // Occupational and Environmental Medicine. - 2012. - Vol. 69. - Р. 268 - 75.
  83. Dinis-Ribeiro M., Areia M., de Vries A. C., et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from theEuropean Society of Gastrointestinal Endoscopy (ESGE), European Heli-cobacter Study Group (EHSG). European Society of Pathology, and theSociedade Portoguesa de Endoscopia Digestiva (SPED) // Endoscopy. - 2012. - Vol. 44. - Р. 74 - 94.
  84. Ивашкин В. Т., Шептулин А. А., Лапина Т. Л. и соавт. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению функциональной диспепсии //Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2012. - № 3. - С. 80 - 92.

Full text is published :
Osadchuk A.M., Davydkin I.L., Gricenko T.A. OVERVIEW BASIC PROVISIONS CONSENSUS OF THE III WORKING ITALIAN GROUP FOR DIAGNOSIS AND TREATMENT OF H.PYLORI-INFECTION. Experimental and Clinical Gastroenterology Journal. 2016;129(05):33-44
Read & Download full text

1. State Organization «Saint-Petersburg I. I. Dzhanelidze Research Institute of Emergency» (St. Petersburg, Russian Federation)
2. State Organization «Saint-Petersburg I. I. Dzhanelidze Research Institute of Emergency» (St. Petersburg, Russian Federation)
3. FMBA FGBUN «Institute of Toxicology of the Federal Medical and Biological Agency (St. Petersburg, Russian Federation)

Keywords:acute poisoning,ethanol,alcoholic fatty liver disease,remaxol

Abstract:The aim of the study was to increase the efficiency of the treatment of acute ethanol intoxication in patients with alcoholic fatty liver disease. The article presents the results which received during the investigation and treatment of 166 patients with acute ethanol intoxication on the background of alcoholic fatty liver disease Patients were assessed by the severity scale APACHE-II. Were studied the dynamics of clinical, laboratory, biochemical parameters, the state of the antioxidant system activity and lipid peroxidation. The study found the effect of the combination hepatoprotective drug remaxol on the many links of metabolism, which was confirmed by the dynamics of biochemical parameters. There was a quick correction of hyperlactatemia, an effective reduction of ALT activity, the absence of reduction of albumin and urea concentration in the somatic period of ethanol poisoning. Period of using remaxol there was improvement in the clinical course of the disease, which manifested by the reduce the incidence of delirium tremens and shorten the duration of treatment of patients.

• References total 11 ⇓ :: .
  1. Еpмолов А. С., Епифанова Н. М., Pомасенко М. В., Лужников Е. А., Ишмухаметов А. И., Голиков П. П., Хватов В. Б., Кукшина А. А., Давыдов Б. В., Куксова Н. С., Федоpова Н. В., Сыpомятникова Е. Д. Pоль гипеpбаpической оксигенации в лечении постгипоксической энцефалопатии токсического генеза. Анестезиология и реаниматология. 1998; 6: 20 - 25.
  2. Ливанов Г. А., Калмансон М. Л., Батоцыренов Б. В., Глушков С. И., Лодягин А. Н. Фармакологическая коррекция последствий гипоксии у больных в токсической коме вследствие острых отравлений ядами нейротропного действия Анестезиология и реаниматология. 2002; 2: 14 - 17
  3. Ливанов Г. А., Батоцыренов Б. В., Калмансон М. Л., Лодягин А. Н., Васильев С. А. Коррекция критических состояний при острых отравлениях ядами нейротропного действия на раннем госпитальном этапе. Скорая медицинская помощь. 2005; Т. 6 (1): 47 - 52.
  4. Ливанов Г. А., Мороз В. В., Батоцыренов Б. В., Лодягин А. Н., Андрианов А. Ю., Базарова В. Г. Пути фармакологической коррекции последствий гипоксии при критических состояниях у больных с острыми отравлениями. Анестезиология и реаниматология. 2003; 2: 51 - 54.
  5. Лужников Е. А., Леженина Н. Ф., Гольдфарб Ю. С., Епифанова Н. М. Особенности формирования и течения токсико-гипоксической энцефалопатии при острых отравлениях веществами нейротоксического действия. Анестезиология и реаниматология. 2005; 6: 4 - 8.
  6. Лужников Е. А., Костомарова Л. Г. Острые отравления: Руководство для врачей. 2-е изд., М.: Медицина, 2000.
  7. Рябов Г. А. Гипоксия критических состояний. М. 1988.
  8. De Pualo J. R., Folstein V. F., Gordon D. Psychiatric screening on a neurological ward. Psychological Medicane. 1980; 10: 125 - 132.
  9. Granger C. Kelly-Hayes M., Johnstone M. Quality and outcome measures for medical rehabilitation. Physical Medicine and Rehabilitation. W. B. Saunders Company. 1996: 239 - 253.
  10. Mahoney F., Barthel D. Functional evaluation: the Barthel Index. MD State Med. J. 1965; 14: 61 - 65.
  11. Токсикология. Национальное руководство под ред. Иванца Н. Н., Анохиной И. П., Винниковой М. А., М., ГЭОТАР-Медиа, 2008

Full text is published :
Livanov G.A., Shikalova I.A., Lodyagin A.N., Glushkov S.I. et al. FEATURES OF PHARMACOLOGICAL CORR ECTION OF ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH ACUTE ETHANOL INTOXICATION. Experimental and Clinical Gastroenterology Journal. 2016;129(05):45-50
Read & Download full text

1. State budget institution of higher professional education «Pavlov First Saint Petersburg State Medical University» under the Ministry of Public Health of the Russian Federation (St. Petersburg, Russian Federation)

Keywords:steatosis,treatment,glycyrrhizin acid,ursodeoxycholic acid

Abstract:Objective: To optimize the diagnostic and therapeutic approaches in polymorbid patients with fatty hepatosis in the practice of general practitioner. The medical tactics of treatment of polymorbidit patient with fatty liver, is considered in regards of the course of concomitant diseases, especially the cardiovascular system. Substantiates the necessity of determination of, in relation to the patient's prognosis, not only the degree of steatosis, but also the liver fibrosis stage changes, developing due to apoptosis of hepatocytes that leads to the progression of endothelial dysfunction A working version of the treatment of hepatic steatosis, designed to reduce progression of fatty degeneration, reducing the risk of steatohepatitis and fibrosis body changes is proposed in the paper. Ursodeoxycholic acid and glycyrrhizin are the most promising medication.

• References total 33 ⇓ :: .
  1. Бабак О. Я., Колесникова Е. В. Участие печени в формировании метаболического синдрома и инсулинорезистентности. Состояние проблемы // Сучасна гастроентерологя. - 2006. - № 4 (30). - C. 8 - 12.
  2. Буеверов А. О. Жирная печень: причины и последствия // Практикующий врач. - 2002. - № 1. - С. 36 - 38.
  3. Буеверов А. О. Оксидативный стресс и его роль в повреждении печени // Рос. журн. гастроэнтерол. гепатол. колопроктол. - 2002. - Т. 12. - № 4. - С. 21 - 25.
  4. Драпкина О. М., Корнеева О. Н. Неалкогольная жировая болезнь печени и сердечно-сосудистый риск: влияние женского пола // Фарматека. - 2010. - № 15. - С. 1 - 5.
  5. Мехтиев С. Н., Зиновьева Е. Н. Современные аспекты патогенетического лечения неалкогольной жировой болезни печени // Эффективная фармакотерапия. Гастроэнтерология. - 2012. - № 4. - С. 24 - 28.
  6. Мехтиев С. Н., Мехтиева О. А. Жировая болезнь печени как фактор изменения риска сердечно-сосудистых «катастроф» у больных артериальной гипертензией // Лечащий врач. - 2015. - № 5. - С. 1 - 6.
  7. Мехтиев С. Н., Мехтиева О. А., Смирнова М. Н. Фиброз печени как показание для терапии у больных хроническими гепатитами // Эффективная фармакотерапия. Гастроэнтерология № 1. - 2015. - № 2. - С. 22 - 34.
  8. Мехтиев С. Н., Зиновьева Е. Н. Соколовский С. В. Эндотелиальная дисфункция как фактор прогрессирования неалкогольного стеатогепатита. Терапевтические подходы // Эффективная Фармакотерапия. - 2011. - № 2. - С. 36 - 44.
  9. Мехтиев С. Н., Степаненко В. В., Зиновьева Е. Н. Современные представления о фиброзе печени и методах его коррекции // Фарматека. - 2014. - № 6. - С. 80 - 87
  10. Павлов Ч. С., Глушенков Д. В., Ивашкин В. Т. Современные возможности эластометрии, фибро- и акти-теста в диагностике фиброза печени // Рос. журн. гастроэнтерол., гепатол. и колопроктол. - 2008. - № 4. - С. 43 - 52.
  11. Павлов Ч. С., Ивашкин В. Т., Шульпекова Ю. О., Золотаревский В. Б. Современные представления о патогенезе, диагностике и лечении фиброза печени // Рос. журн. гастроэнтерол., гепатол., колопроктол. - 2005. - Т. 15. - № 2. - С. 13 - 20.
  12. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями (под ред. И. Е. Чазова) // Кардиологический вестник. - 2014. - Т. 20. - № 1. - С. 1 - 58.
  13. Ройтберг Г. Е., Шархун О. О., Кондратова Н. В., Ушакова Т. И. Роль метаболического синдрома и его компонентов в патогенезе и прогрессировании неалкогольного стеатогепатита // Гепатология. - 2005. - № 5. - С. 30 - 36.
  14. Сторожаков Г. И., Ивкова А. Н. Патогенетические аспекты фиброгенеза при хронических заболеваниях печени // Клин. перспективы гастроэнтерологии, гепатологии. - 2009. - № 2. - С. 3 - 10.
  15. Шерлок Ш., Дули Дж. Заболевания печени и желчных путей: Практическое руководство. - М.: ГЭОТАР-МЕД, 2002. - 864 с.
  16. Aird WC. Endothelium as an organ system. Crit Care Med 2004;32 (5 Suppl):S271-279. [PubMed: 15118530].
  17. Bataller R., Brenner D. A. Liver fibrosis // J. Clin. Invest., 2005; 115 (2): 209 - 218.
  18. Bellentani S., Scaglioli F., Marino M., Bedogni G. Epidemiology of non - alcoholic fatty liver disease // Dig. Dis. - 2010. - № 28. - Р. 155 - 161.
  19. Casino P., Kilcoyne C. M., Quyyumi A. A., Hoeg J. M., Panza J. A. The role of nitric oxide in endothelium-dependent vasodilatation of hypercholesterolemic patients // Circulation. - 1993; 88: 2541 - 2547.
  20. Diehl A. M. Nonalcoholic steatosis and steatohepatitis IV: nonalcoholicfatty liver disease abnormalities in macrophage function and cytokines // Am. J. Physiol. - 2002;282: G1 - G5.
  21. Friedman S. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications // Nat. Clin. Prac. Gastroenterol. Hepatol. - 2004; 1: 98 - 105.
  22. Frith J., Day C. P., Henderson E., Burt A. D., Newton J. L. Non-alcoholic fatty liver disease in older people // GERONTOLOGY. - 2009. - № 55 (6). - Р. 607 - 613.
  23. Hamaguchi M., Kojima T., Takeda N., et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease // World J. Gastroenterol. - 2007;13 (10):1579 - 84.
  24. Heil S. G., De Vriese A. S., Kluijtmans L. A., Mortier S., Den Heijer M., Blom H. J. The role of hyperhomocysteinemia in nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF) - mediated vasodilatation. Cell Mol Biol (Noisy-le-grand) 2004; 50 (8):911 - 916. [PubMed: 15704255].
  25. Ogawa E., Furusyo N., Toyoda K. et al. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with with pegylated interferon alpha-2d and ribavirin // Antiviral Res. - 2009; 83 (2): 127 - 134.
  26. Parsons C. J., Takashima M., Rippe R. A. Molecular mechanisms of hepatic fibrogenesis // J. Gastroenterol. Hepatol. - 2007; 22 (1):79 - 84.
  27. Poynard T., Zoulim F., Ratziu V. et al. Longitudinal assessment of histology surrogate markers (FibroTest - ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection // Am. J. Gastroenterol. - 200; 100: 1970 - 1980.
  28. Rockey D. C. Antifibrotic therapy in chronic liver disease // Clin. Gastroenterol. Hepatol. - 2005; 3: 95 - 107.
  29. Torres D. M., Williams C. D., Harrison S. A. Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease / Cl. Gastroenter. Hepatol. 2012; 10: 837 - 858.
  30. Vane J., Annggard E. E., Botting R. M. Regulatory function of the vascular endothelium // N. Engl. J. Med. - 1990; 323: 27 - 36.
  31. Vernon G., Baranova A., Younossi Z. M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults // Aliment. Pharmacol. Ther. - 2011. № 34. - Р. 274 - 285.
  32. Wang Z. Y., Nixon D. W. Licorice and cancer // Nutr. Cancer. 2001. Vol. 39. № 1. P. 1 - 11.
  33. Zois C., Baltayiannis G., Karayiannis P., Tsianos E. Systematic review: hepatic fibrosis - regression with therapy // Aliment. Pharmacol. Ther. - 2008; 28: 1175 - 1187.

Full text is published :
Mehtiyev S.N., Mehtiyeva O.A. NEW PARADIGM CHALLENGES OF STEATOSIS TREATMENT IN THE PRACTICE THERAPIST. Experimental and Clinical Gastroenterology Journal. 2016;129(05):51-57
Read & Download full text

1. I. M. Sechenov First Moscow State Medical University (Moscow, Russian Federation)
2. Pirogov Russian National Research Medical University (Moscow, Russian Federation)
3. Moscow Regional Research Clinical Institute named after M. F. Vladimirsky (Moscow, Russian Federation)

Keywords:birth defects,anorectal malformations,epidemiology,etiology,incidence

Abstract:The review presents an analysis of current data on the epidemiology, etiology, clinical and genetic characteristics of congenital anorectal malformations (AM). According to international registers of congenital malformations prevalence of the AM varies from 2 to 5 per 10,000 births. There was no change in the prevalence over time of AM (absence of temporal trends). Most studies have indicated the predominance of males among patients with AM. Approximately 40 - 70% of patients with AM have congenital malformations of other organs and systems. The data on the participation of genetic and environmental factors in the origin of the AM. A brief clinical and genetic characteristics of the most common syndromes (association) with the AM.

• References total 55 ⇓ :: .
  1. Hartman EE, Oort FJ, Aronson DC, Sprangers MA. Quality of life and disease-specific functioning of patients with anorectal malformations or Hirschsprung’s disease: a review. 2011 Arch Dis Child, 2011; 96:398 - 406.
  2. Stephens FD, Smith DE. Anorectal malformations in children. Chicago: Yearbook Publishers Inc. 1971; p 133.
  3. Stephens FD, Smith ED, Paoul NW. Anorectal malformations in children: update. March of Dimes Birth Defect Foundation Original series, 1988; vol. 24
  4. Stephens FD, Durham-Smith E. Classification, identification, and assessment of surgical treatment of anorectal anomalies. Pediatr Surg Int, 1986; 1: 200 - 205.
  5. Pena A. Anorectal malformations. Semin Pediatr Surg. 1995;4:35 - 47
  6. Ленюшкин А. И. Колопроктология детского возраста. Руководство для врачей. Медицина. 1999. - 365 С.
  7. Smith ED. Incidence, frequency of types and aetiology of anorectal malformations. Birth Defects Orig Artic, 1988; Ser 24 (4):231 - 246
  8. Harris J, Kallen B, Robert E. Descriptive epidemiology of alimentary tract atresia. Teratology, 1995; 52:15 - 29.
  9. A Cuschieri and EUROCAT Working Group. Descriptive Epidemiology of Isolated Anal Anomalies: A Survey of 4.6 Million Birth in Europe. Am J Med Genet, 2001; 103: 207 - 15.
  10. Forrester MB, Merz RD. Risk of Selected Birth Defects with Prenatal Illicit Drug Use, Hawaii, 1986 - 2002. J Toxicol Environ Health A. 2007; 70: 7 - 18.
  11. Sun G, Xu ZM, Laing JF, LiL, Tang DX. Twelve-year prevalence of common neonatal congenital malformations in Zhejiang Province, China. World J Pediatr, 2011; 7: 331 - 336
  12. Almaramhy, Hamdi H. Incidence and spectrum of anorectal malformations in Western Saudi Arabia. Saudi Medical Journal, 2012: Vol. 33, No 12:
  13. Stoll C, Alembik Y, Roth MP, Dott B. Risk factors in congenital analatresias. Ann Genet. 1997; 40: 197 - 204.
  14. Yang JH, et al. A multi-center study for birth defect monitoring. Arch Pediatr Adolesc Med, 2004; 155: 587 - 591
  15. Landau, D., Mordechai, J., Karplus, M., Carmi, R. Inheritance of familial congenital isolated anorectal malformations: case report and review. Am. J. Med. Genet, 1997; 71: 280 - 282.
  16. Falcone RA Jr, MA Levitt, A Peña, M Mates, Increased heritability of certain types of anorectal malformations. J Pediatr Surg, 2007; 42, 124 - 8.
  17. Wijers CH, de Blaauw I, Marcelis CL, et al. Research perspectives in the etiology of congenital anorectal malformations using data of the International Consortium on Anorectal Malformations: evidence for risk factors across different populations. Pediatr Surg Int, 2010; 26:1093 - 1099
  18. Zhang J, Zhang ZB, Gao H, et al. Down-regulation of SHH/BMP4 Signalling in Human Anorectal Malformations. J Int Med Res, 2009; 37:1842 - 1850
  19. Carter TC, Kay DM, Browne ML, et al. Anorectal atresia and variants at predicted regulatory sites in candidate genes. AnnHumGenet, 2013; 77:31 - 46
  20. Moore SW, Zaahl MG. Association of endothelin-beta receptor (EDNRB) gene variants in anorectal malformations. J Pediatr Surg. 2007 Jul; 42 (7):1266 - 70
  21. Zhang T, Tang XB, Wang LL, et al. Mutations and down-regulation of CDX1 in children with anorectal malformations. Int J MedSci, 2013; 10:191 - 197
  22. Lickert H., Domon C., Huls G., Wehrle C., Duluc I., Clevers H. et al. Wnt/ (beta) - catenin signaling regulates the expression of the homeobox gene Cdx1 in embryonic intestine. Development, 2000; 127: 3805 - 3813
  23. Wong EH, Cui L, Ng CL, et al. Genome-wide copy number variation study in anorectal malformations. Hum Mol Genet, 2013; 22: 621 - 631
  24. Wijers CH, van Rooij IA, Marcelis CL et al. Genetic and nongenetic etiology of nonsyndromic anorectal malformations: a systematic review. Birth Defects Res C Embryo Today 2014;102:382 - 400.
  25. Hay S, Barbano H. Independent effects of maternal age and birth order on the incidence of selected congenital malformations. Teratology 1972; 6:271 - 279.
  26. Myers MF, Li S, Correa-Villaseñor A, et al. Folic acid supplementation and risk for imperforate anus in China. Am J Epidemiol 2001;154:1051 - 1056.
  27. van Rooij IA, Wijers CH, Rieu PN, et al. Maternal and Paternal Risk Factors for anorectalMalformations: A Dutch Case-Control Study. Birth Defects Res A ClinMolTeratol, 2010; 88, 152 - 8
  28. Wijers CHW, van Rooij IALM, Bakker MK, et al. Anorectal malformations and pregnancy-related disorders: a registry-based case-control study in 17 European regions. BJOG 2013; 120:1066 - 1074.
  29. Forrester MB, Merz RD. Descriptive epidemiology of anal atresia in Hawaii, 1986 - 1999. Teratology 2002; 66 Suppl 1: S12-16.
  30. Miller EA, Manning SE, Rasmussen SA, et al. Maternal exposure to tobacco smoke, alcohol and caffeine, and risk of anorectal atresia: National Birth Defects Prevention Study 1997 - 2003. Paediatr Perinat Epidemiol, 2009; 23:9 - 17.
  31. Källén B, Finnström O, Nygren KG, et al. In vitro fertilization (IVF) in Sweden: risk for congenital malformations after different IVF methods. Birth Defects Res A Clin Mol Teratol, 2005; 73:162 - 169.
  32. Midrio P, Nogare CD, Di GE, et al. Are congenital anorectal malformations more frequent in newborns conceived with assisted reproductive techniques? Reprod Toxicol 2006; 22:576 - 577.
  33. Reefhuis J, Honein MA, Schieve LA, et al. Assisted reproductive technology and major structural birth defects in the United States. Hum Reprod., 2009; 24:360 - 366.
  34. Zwink N, Jenetzky E, Schmiedeke E, et al. Assisted reproductive techniques and the risk of anorectal malformations: a German case-control study. Orphanet J Rare Dis, 2012; 7:65.
  35. Waller DK, Shaw GM, Rasmussen SA, et al. Prepregnancy obesity as a risk factor for structural birth defects. Arch Pediatr Adolesc Med, 2007; 161:745 - 750.
  36. Frías JL, Frías JP, Frías PA, et al. Infrequently studied congenital anomalies as clues to the diagnosis of maternal diabetes mellitus. Am J Med Genet. A, 2007; 143A: 2904 - 2909.
  37. Correa A, Gilboa SM, Besser LM, et al. Diabetes mellitus and birth defects. Am J Obstet Gynecol., 2008; 199:237 - 239.
  38. Feldkamp ML, Meyer RE, Krikov S, et al. Acetaminophen use in pregnancy and risk of birth defects: findings from the National Birth Defects Prevention Study. Obstet Gynecol 2010; 115:109 - 115.
  39. Broussard CS, Rasmussen SA, Reefhuis J, et al. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol 2011; 204:314 e311-311.
  40. van Gelder MM, Roeleveld N, Nordeng H. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and the risk of selected birth defects: a prospective cohort study. PLoS One 2011; 6: e221-274.
  41. Crider KS, Cleves MA, Reefhuis J, et al. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med, 2009;163:978 - 985.
  42. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40:1723 - 1733.
  43. Bonnot O, Vollset SE, Godet PF, et al. Maternal exposure to lorazepam and anal atresia in newborns: results from a hypothesis-generating study of benzodiazepines and malformations. JClin Psychopharmacol, 2001; 21:456 - 458.
  44. Eros E, Czeizel AE, Rockenbauer M, et al. A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2002; 101:147 - 154.
  45. Czeizel AE, Eros E, Rockenbauer M, et al. Short-Term Oral Diazepam Treatment during Pregnancy: A Population-Based Teratological Case-Control Study. Clin Drug Investig 2003; 23:451 - 462.
  46. Czeizel AE, Rockenbauer M, Sorensen HT, et al. A population-based case-control study of oral chlordiazepoxide use during pregnancy and risk of congenital abnormalities. Neurotoxicol Teratol, 2004;26:593 - 598.50
  47. Kjaer D, Horvath-Puhó E, Christensen J, et al. Use of phenytoin, phenobarbital, or diazepam during pregnancy and risk of congenital abnormalities: a case-time-control study. Pharmacoepidemiol Drug Saf 2007; 16:181 - 188.
  48. Herdt-Losavio ML, Lin S, Chapman BR, Hooiveld M, et al. Maternal occupation and the risk of birth defects: an overview from the National Birth Defects Prevention Study. Occup Environ Med., 2010; 67, 58 - 66. doi: 10.1136/oem. 2009.048256
  49. Yuan P, Okazaki I, Kuroki Y. Anal atresia: effect of smoking and drinking habits during pregnancy. Jpn J Hum Genet. 40, 1995; 327 - 32
  50. Zwink et al. Orphanet Journal of Rare Diseases, 2011; 6:25http://www.ojrd.com/content/6/1/25Page 15 of 16
  51. Honein MA, Paulozzi LJ, Watkins ML, Maternal smoking and birth defects: validity of birth certificate data for effect estimation. Public Health Rep., 2001; 116,327 - 35.
  52. Jenetzky E, Prevalence estimation of anorectal malformations using German diagnosis related groups system. PediatrSurgInt, 2007; 23:1161 - 1165
  53. Holschneider A, Hutson J, Pen˜a A, Beket E, et al. Preliminary report on theInternational Conference for the Development of Standards forthe Treatment of Anorectal Malformations. J PediatrSurg, 2005; 40:1521 - 1526
  54. Marcelis C, de Blaauw I, Brunner H. Chromosomal anomalies in the etiology of anorectal malformations: A review. Am J Med Genet Part A, 2011; 9999: 1 - 13 www.omim.org
  55. Sam W Moore. Associations of anorectal malformations and related syndromes. Pediatr Surg Int, 2013; 29, 665 - 676

Full text is published :
Vydrych Yu.V., Demikova N.S., Filyushkin Yu.N., Kalinenkova S.G. et al. EPIDEMIOLOGICAL, CLINICAL AND GENETIC CHARACTERISTICS OF ANORECTAL MALFORMATIONS (REVIEW). Experimental and Clinical Gastroenterology Journal. 2016;129(05):58-64
Read & Download full text

1. State Budget Educational Institution of Higher Professional Education (SBEI HPE) «A. I. Evdokimov Moscow State University of Medicine and Dentistry Ministry of Healthcare of Russia» (Moscow, Russian Federation)

Abstract:The paper reflects the issues of pathogenesis of the chronic liver diseases (CLD). The role of the cell membrane lipid peroxidation as well as oxidative stress and fibrosis formation in the development and progression of liver lesions of various aetiologies. are represented in details. Particular attention is given to the justification of pathogenetic approaches to the treatment of liver disease. Presented the evidence base of successful application of the standardized silymarin as a part of the drug Legalon in the CLD of different etiology.

• References total 58 ⇓ :: .
  1. Барабой В. А., Сутковой Д. А. Окислительно-антиоксидантный гомеостаз в норме и патологии / Под. ред. акад. АМН Украины Ю. А. Зозули. - К.: Чернобыльинтеринформ, 1997. - Ч. 1, 2.
  2. Васильева Е. М., Баканов М. И., Поддубная А. Е., Шор Т. А. Перекисное окисление липидов при неврологической патологии у детей // Клиническая лабораторная диагностика. - 2005. - № 2. - С. 8 - 12.
  3. Голованова Е. В. Механизмы фиброзообразования при хронических заболеваниях печени и возможности антифибротической терапии. Consilium Medicum, - 2014. № 8 (том 16), стр. 52 - 59.
  4. Голованова Е. В. Технология проведения пункционной биопсии печени (рекомендации НОГР). «Экспериментальная и клиническая гастроэнтерология», № 5, 2009, стр. 140 - 144.
  5. Голованова Е. В., Логинов А. Ф. Фиброз при хронических заболеваниях печени. Возможности антифибротической терапии. Учебно-методическое пособие для врачей. Институт усовершенствования врачей ФГБУ «НМХЦ им. Н. И. Пирогова» Минздрава России, Москва, 2013. С. 30.
  6. Зозуля Ю. А., Барабой В. А., Сутковой Д. А. Свободнорадикальное окисление и антиоксидантная защита при патологии головного мозга. - М.: Знание-М., 2000. - 9 с.
  7. Казимирко В. К., Мальцев В. И. Aнтиоксидантная система и ее функционирование в организме человека // http: www.health-ua.com /2004
  8. Коровина Н. А., Захарова И. Н., Обыночная Е. Г. Применение антиоксидантов в педиатрической практике // http: media consilium/03_09/ Feb - 2004.
  9. Курашвили В. А., Майлэм Л. Новые возможности предотвращения оксидативного стресса // Журнал натуральной медицины. - 2001. - № 1. - С. 7 - 14.
  10. Лазебник Л. Б., Радченко В. Г., Голованова Е. В. и соавт. Неалкогольная жировая болезнь печени: клиника, диагностика, лечение. Клинические рекомендации НОГР. - Экспериментальная и клиническая гастроэнтерология - 2015. - № 119 (7) - C. 85 - 96.
  11. Лещинский Л. Д. Обоснование и опыт применения ряда ингибиторов перекисного окисления липидов у больных ишемической болезнью сердца // ТОП-Медицина. - 1998. - № 4. - С. 17 - 21.
  12. Марри Р., Греннер Д., Мейес П., Родуэлл В. Биохимия человека. - М., 1993. - Т. 1 - 2. - 779 с.
  13. Овсянникова Л., Носач Е. Антиоксидантные препараты: проблема выбора // Doctor. - 2003. - № 1. - С. 74 - 76.
  14. Суханова Г. А., Серебров В. Ю. Биохимия клетки. - Томск: Чародей, 2000. - С. 91 - 142.
  15. Щербаков А. Е. Исследование показателей перекисного окисления липидов и антиоксидантной системы в комплексе мероприятий вторичной профилактики инсультов // http: www.rusmedserv.com/ 2000
  16. Яворская В. А, Малахов В. А., Белоус А. М. Интенсивность процессов перекисного окисления липидов и активность антиоксидантных ферментов в эритроцитах при начальных формах сосудистых заболеваний головного мозга // Неврологический вестник. - 1995. - Т. XXVII, вып. 3 - 4. - С. 15 - 17.
  17. Afdhal N. H., Nunes, D. Evaluation of liver fibrosis: a concise review. // Am. J. Gastroenterol. 2004. - 99:1160 - 1174.
  18. Albanis E., Friedman S. L. Hepatic fibrosis. Pathogenesis and principles of therapy. // Clin. Liver Dis. 2001;5:315 - 334
  19. Albano E, Mottaran E, Vidali M, et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut. 2005; 54 (7): 987 - 93.
  20. Allard JP, Aghdassi E, Mohammed S, et al. Nutritional assessment and hepatic fatty acid composition in nonalcoholic fatty liver (NAFLD):a cross-sectional study. J Hepatol. 2008; 48 (2): 300 - 7.
  21. Barreyro FJ, Kobayashi S, Bronk SF, et al. Transcriptional regulation of Bim by FoxO3a mediates hepatocyte lipoapoptosis. J Biol Chem. 2007; 282 (37): 27141 - 54.
  22. Bataller R., Brenner D. A. Hepatic stellate cells as a target for the treatment of liver fibrosis. // Semin. Liver Dis. 2001.21:437 - 451
  23. Benyon R. C., Iredale, J. P. Is liver fibrosis reversible? // Gut. 2000.46:443 - 446
  24. Caballero F, Fernández A, Matías N, et al. Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione. J Biol Chem. 2010; 285 (24): 18528 - 36.
  25. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2004; 99 (8): 1497 - 502.
  26. Chavin KD, Yang S, Lin HZ, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem. 1999; 274: 5692 - 700.
  27. Dehmlow С., Erhard J., Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of Silibinin //Life Sci. 58, 749 - 754, 1996
  28. Echtay KS, Murphy MP, Smith RA, et al. Superoxide activates mitochondrial uncoupling protein 2 from the matrix side. Studies using targeted antioxidants. J Biol Chem. 2002; 277.
  29. Esterbauer H., Gebicki J., Puhl H., Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL // Free Radic. Biol. Med. - 1992. - № 13. - P. 341 - 390.
  30. Ferenci et al. // J. Hepatol. 1989. - № 9, 105 - 113,
  31. Frei B., Stocker R., Ames B. N. Antioxidant defenses and lipid peroxidation in human blood plasma // Proc. Natl. Acad. Sci. USA. - 1988. - № 85. - Р. 9748 -9752.
  32. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. // Semin. Liver Dis. 2001.21:311 - 335.
  33. Halliwell B. O., Gutteridge J. M. C. Free radicals in biology and medicine. - Oxford: Clarendon Press, 1989.
  34. Hardwick JP, Osei-Hyiaman D, Wiland H, et al. PPAR/RXR regulation of fatty acid metabolism and fatty acid ω-hydroxylase (CYP4) isozymes: Implications for prevention of lipotoxicity in fatty liver disease. PPAR Res. 2009: 9527 - 34.
  35. Ikura Y, Ohsawa M, Suekane T, et al. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology. 2006; 43 (3): 506 - 14.
  36. Jia et al., Hepatology 28, 546A, 1998
  37. Kodama Y, Brenner DA. C-Jun N-terminal kinase signaling in the pathogenesis of nonalcoholic fatty liver disease: multiple roles in multiple steps. Hepatology. 2009; 49 (1): 6 - 8.
  38. Krinsky N. L. Membrane antioxidants // Ann. NY. Acad. Sci. - 1988. - № 551. - Р. 17 - 33.
  39. Ladas EJ, Kroll DJ, Oberlies NH, Cheng B, Ndao DH, Rheingold SR, Kelly KM. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). // Cancer. 2010;116 (2):506 - 13
  40. Leclercq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest. 2000; 105:1067 - 75.
  41. Lieber CS. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab Rev. 2004; 36 (3-4): 511 - 29.
  42. Madan K, Bhardwaj P, Thareja S, et al. A. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J Clin Gastroenterol. 2006; 40 (10): 930 - 35.
  43. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis. 2008; 28 (4): 360 - 9.
  44. McClain CJ, Mokshagundam SP, Barve SS, et al. Mechanisms of non-alcoholic steatohepatitis. Alcohol. 2004; 34: 67 - 79.
  45. Mourelle et al., Fundam. // Clin. Pharmacol. 3, 183 - 191,1989
  46. Nair J, Srivatanakul P, Haas C, et al. High urinary excretion of lipid peroxidation-derived DNA damage in patients with cancer-prone liver diseases. Mutat Res. 2010; 683: 23 - 8.
  47. Payer B. A., Reiberger T., Rutter K. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV - HCV coinfected patient //Journal of Clinical Virology 49 (2010) 131 - 133
  48. Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2007; 22 suppl 1: 20 - 7.
  49. Ramasamy K, Agarwal R. //Cancer Lett. 2008;269 (2):352 - 62
  50. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol. 2001; 281 (5): 1135 - 9.
  51. Rockey D. C. // Clin Gastroenterol Hepatol 2005; 3: 95 - 107.
  52. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Non alcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001; 120 (5): 1183 - 92.
  53. Schuppan D., Pinzani M. Anti-fibrotic therapy: Lost in translation? //J. of Hepatology, Suppl. 1 (Vol. 56). - 2012. - P. S56-S74.
  54. Schuppan, Z. //Allg. Med. 74, 577 - 584, 1998
  55. Seeff LB, Curto TM, Szabo G. et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. //Hepatology 2008;47:605 - 612.
  56. Seki S, Kitada T, Sakaguchi H. Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatol Res. 2005; 33 (2): 132 - 4.
  57. Syn WK, Yang L, Chiang DJ, et al. Genetic differences in oxidative stress and inflammatory responses to dietinduced obesity do not alter liver fibrosis in mice. Liver Int. 2009; 29 (8): 1262 - 72.
  58. Weltman MD, Farrell GC, Hall P, et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology. 1998; 27 (1): 128 - 33.

Full text is published :
Golovanova E.V. THE PATHOGENETIC APPROACHES TO THE CHRONIC LIVER DISEASES TREATMENT. Experimental and Clinical Gastroenterology Journal. 2016;129(05):65-73
Read & Download full text